WHO leaves lung cancer drugs off its ‘essential list’

11 Jul 2019

The list, which includes treatments that the WHO regards as global standards that should be available everywhere, aims to help governments make the best choices for their health systems.

The WHO added 28 new medicines to the latest edition but rejected Keytruda from Merck, Opdivo from Bristol-Myers Squibb and Tecentriq from Roche for non-small cell lung cancer, where they have combined for billions of dollars in sales in recent years.